HPC
BMY.RT

HM Payson & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

HM Payson & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,971
Closed -$3K – 1215
2020
Q4 		$3K Sell
3,971
-850
-18% -$1.81K ﹤0.01% 1000
2020
Q3 		$11K Buy
4,821
+1,574
+48% +$4.5K ﹤0.01% 823
2020
Q2 		$11K Hold
3,247
– – ﹤0.01% 741
2020
Q1 		$12K Sell
3,247
-3,900
-55% -$12.8K ﹤0.01% 720
2019
Q4 		$22K Buy
+7,147
New +$18.6K ﹤0.01% 711

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

HM Payson & Co's BMY.RT Position: Q1 2021 in Review

HM Payson & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,971 shares — an estimated $3K sold.

HM Payson & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $22K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • HM Payson & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • HM Payson & Co sold 3,971 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3K.
  • HM Payson & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • HM Payson & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $22K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on HM Payson & Co's 13F filing for Q1 2021, filed 15 Jun 2021.